The incremental cost-effectiveness ratio of group A as against group B was41.CONCLUSION:Levofloxacin is of better cost-effectiveness advantage than gatifloxacin in the treatment of acute bacterial infections.

• A组相对于B组的增量成本-效果比为41。 结论与加替沙星比较,左氧氟沙星治疗急性细菌性感染更具成本-效果优势。